与性结肠炎相关的分子标和基于阿特拉基胺的治疗的好处
Huanzhu Qian1, Zhen Ye1, Yu Hu1
1School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
氨基胺 (ATs) 通过调节免疫屏障,减少氧化应激和调节肠道微生物群来治疗性结肠炎 (UC) 是有前途的. 这些天然化合物也可能有助于管理UC并发症,提供新的治疗途径.
科学领域:
- 自然产品 化学 化学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种具有重大影响生活质量的慢性炎症性肠病.
- 目前的UC治疗 (5-ASA,皮质类固醇,免疫抑制剂,生物药物) 有局限性.
- 来自*Atractylodes macrocephala*的atractylenolides (AT) 是一种具有潜在治疗益处的天然化合物.
研究的目的:
- 系统地审查ATs在治疗UC中的疗效.
- 探索AT在UC治疗和并发症管理中的潜在机制.
- 为未来的研究和AT在UC的临床应用提供见解.
主要方法:
- 关于AT和UC的研究的文献综述.
- 对ATs对免疫屏障,氧化应激,肠道微生物群,线粒体功能和肠道修复的影响的研究分析.
- 检查AT的抗纤维化,抗血栓,抗血管生成和抗癌性质.
主要成果:
- 通过免疫调节,氧化应激减轻,肠道微生物群调节和改善线粒体功能,ATs在UC治疗中表现出有效性.
- ATs有助于肠道屏障的修复.
- ATs在管理UC并发症方面表现出潜力,包括纤维化,血栓形成,血管生成和癌症.
结论:
- ATs显示出治疗性结肠炎及其相关并发症的巨大潜力.
- 多方面的AT机制为UC提供了一个有前途的治疗策略.
- 需要进一步的研究和临床试验,以充分确定AT在UC管理中的作用.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
